Trials Boost Hopes for Low-Cost Meningitis Vaccine

PUNE, India; GENEVA; SEATTLE, -- The Meningitis Vaccine Project (MVP), a partnership between the World Health Organization (WHO) and Seattle-based nonprofit, PATH, and the Serum Institute of India Limited (SIIL) announced today the successful completion of their Phase I clinical trial of a new conjugate vaccine against serogroup A meningococcus, a bacterium that causes deadly meningitis epidemics and much human suffering in sub-Saharan Africa.

To read the full press release, visit the PATH Web site.